Trials / Completed
CompletedNCT01249131
A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants
A Phase I, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of GDC-0973 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will be an open-label, randomized, 3-way, 6-sequence crossover study in healthy participants for determining the relative bioavailability of the tablet formulation to the capsule formulation and the effect of food on the relative bioavailability of the tablet formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cobimetinib | Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2011-01-10
- Completion
- 2011-01-10
- First posted
- 2010-11-29
- Last updated
- 2017-08-15
- Results posted
- 2016-07-18
Source: ClinicalTrials.gov record NCT01249131. Inclusion in this directory is not an endorsement.